Your browser is no longer supported. Please, upgrade your browser.
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E3163.85 EPS (ttm)0.01 Insider Own0.20% Shs Outstand2.42B Perf Week-1.32%
Market Cap99.73B Forward P/E15.02 EPS next Y2.74 Insider Trans0.00% Shs Float2.42B Perf Month-5.62%
Income38.00M PEG316.38 EPS next Q0.80 Inst Own9.10% Short Float0.27% Perf Quarter-5.55%
Sales30.84B P/S3.23 EPS this Y204.10% Inst Trans0.24% Short Ratio2.46 Perf Half Y-1.93%
Book/sh0.29 P/B141.83 EPS next Y5.55% ROA0.10% Target Price48.67 Perf Year6.43%
Cash/sh2.36 P/C17.42 EPS next 5Y10.00% ROE0.90% 52W Range35.91 - 45.07 Perf YTD7.77%
Dividend1.87 P/FCF- EPS past 5Y40.20% ROI41.40% 52W High-8.74% Beta0.91
Dividend %4.55% Quick Ratio0.60 Sales past 5Y-3.40% Gross Margin66.60% 52W Low14.53% ATR0.55
Employees101192 Current Ratio0.90 Sales Q/Q10.90% Oper. Margin5.30% RSI (14)34.92 Volatility0.80% 1.03%
OptionableYes Debt/Eq34.12 EPS Q/Q-392.80% Profit Margin0.10% Rel Volume0.86 Prev Close41.43
ShortableYes LT Debt/Eq26.30 EarningsOct 26 Payout- Avg Volume2.69M Price41.13
Recom2.00 SMA20-3.50% SMA50-4.91% SMA200-0.41% Volume2,301,794 Change-0.72%
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Oct-21-16 06:04PM  Do Analysts Expect Negative Growth for Novartis in 3Q16?
03:47PM  Whats to Be Expected from Novartiss 3Q16 Earnings?
09:27AM  GlaxoSmithKline (GSK) Q3 Earnings: What's in the Cards?
07:45AM  Why Despite Alkermes Success, Suicidal Ideation Still Eludes Big Pharma at 24/7 Wall St.
Oct-20-16 10:24AM  Better Buy: Pfizer Inc. vs. GlaxoSmithKline plc at Motley Fool
08:17AM  [video]These 5 Big-Cap Stocks Are Breaking Out After the Debate: Alphabet, Visa and More
07:11AM  Coverage initiated on GlaxoSmithKline by Investec
Oct-19-16 10:27AM  WHO seeks new mechanism for crisis vaccine supplies at low cost Reuters
12:05AM  GlaxoSmithKline Plc (GSK) Shrugs Skeptics Concerns To Launch Cold Flu Tracker App at Insider Monkey
Oct-18-16 06:10PM  Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc. at Motley Fool
05:21PM  Eli Lillys 3Q16 Earnings: What to Expect
Oct-17-16 02:25PM  Why You Should Wait to Buy These 3 Stocks at Motley Fool
Oct-14-16 11:43AM  GlaxoSmithKline Plc : GSK-US: Dividend Analysis : August 12th, 2016 (record date) : By the numbers : October 14, 2016
Oct-13-16 01:20PM  Shark Tank's O'Leary Bullish on GlaxoSmithKline (GSK)
12:24PM  BofA: Expect upside to Merck estimates
12:03PM  WHO warns global tuberculosis fight is billions of dollars behind at MarketWatch
10:40AM  Heres What We Want To See From Adaptimmune Therapeutics PLC ADR (ADAP) at Insider Monkey
10:00AM  World Health Organization warns that global tuberculosis fight is billions of dollars behind at MarketWatch
Oct-12-16 05:18PM  Is Brexit a Buying Opportunity?
01:27PM  How GILD Plans to Battle through Impending HIV Patent Cliff
09:30AM  The Zacks Analyst Blog Highlights: Chevron, Cisco Systems, GlaxoSmithKline, NIKE and BP
08:35AM  4 Contrarian Stocks to Buy Yielding 5% or More With Big Upside Potential at 24/7 Wall St.
Oct-11-16 06:17PM  Tweedy Browne Adds to 5 Holdings, Trims 2 Others in 3rd Quarter
01:36PM  Why Doctors Without Borders is turning down a million free pneumonia vaccines from Pfizer
12:19PM  Top Research Reports for Chevron, Cisco & GlaxoSmithKline
Oct-10-16 12:08PM  Which Big Pharma Is the Best Dividend Stock? at Motley Fool
Oct-09-16 09:43AM  How Much Potential Does Idera Pharmaceuticals' Pipeline Really Have? at Motley Fool
Oct-05-16 01:37PM  Will Gilead (GILD) Stock Fall as RBC Warns of HIV Competition?
10:04AM  How Much Return Could Gilead Offer in the Next Year?
09:56AM  Gilead Sciences: More Competition?!?! at
Oct-04-16 12:12PM  Pound Slump Highlights Brexit Concerns, Lifts FTSE to Near Record
08:05AM  Genvoya Could Be Gilead Sciences Potential Growth Driver
07:22AM  Zika vaccine race spurred by crisis and profit potential
Oct-03-16 12:44PM  Novartis Is Surviving
11:03AM  Gilead: Will New HIV Drugs Overshadow Hep C Worries? at
10:50AM  ETFs with exposure to GlaxoSmithKline Plc : October 3, 2016
10:15AM  Bond Bull Market Is Over: Switch to These 4 Top Dividend Stocks Now at 24/7 Wall St.
10:06AM  Diabetes Care Market Is Expected to See Fast Growth
Oct-01-16 08:45PM  Strong Revenue Points to Gains at GlaxoSmithKline
11:42AM  Better Buy: GlaxoSmithKline plc vs. Johnson & Johnson at Motley Fool
Sep-30-16 06:45PM  Glaxo paying $20M to resolve SEC charges of China bribery
05:05PM  [$$] GlaxoSmithKline to Pay $20 Million to Settle SEC Bribery Probe at The Wall Street Journal
03:04PM  GlaxoSmithKline to pay $20 mln to settle U.S. foreign bribery case Reuters
02:18PM  Glaxo to Pay $20 Million SEC Fine Over Bribing Chinese Officials
02:18PM  Glaxo to Pay $20 Million SEC Fine Over Bribery in China at Bloomberg
02:18PM  GlaxoSmithKline to pay $20 mln to settle foreign bribery related charges Reuters
01:25PM  The Highest-Yielding Drug Stocks at Motley Fool
11:05AM  Which Pfizer Products Reported Declining Sales?
11:05AM  Understanding Strong Growth Trends in Insulin and Novo Nordisks Profitability
10:05AM  Novo Nordisk Continues to Be a Leader in the Global Insulin Market
08:05AM  Why Novo Nordisk Expects Double-Digit Growth in Diabetes Care in 2016
Sep-29-16 03:04PM  Diabetes Care Market Expected to Offer Strong Growth for Novo Nordisk
09:52AM  GlaxoSmithKline (GSK) Stock Down, McNamara Named CEO of Consumer Healthcare Unit
08:40AM  Glaxo Appoints Brian McNamara Chief of Consumer Health Division at Bloomberg
08:20AM  After CEO move, GSK picks ex-Novartis exec to head consumer unit
04:16AM  Aspen Sinks to Four-Month Low as Volumes Surge After Glaxo Sells
Sep-28-16 03:14PM  Ariel Funds Comments on GlaxoSmithKline plc
01:58PM  John Rogers' Ariel Global Fund 2nd Quarter Commentary
12:21PM  Glaxo Sells Stake in South Africas Aspen for $619 Million at Bloomberg
10:05AM  Teva Is Well Placed to Dominate the European Generics Market
09:55AM  GlaxoSmithKline Vaccines for Malaria, Zika Make It a Likely Winner
09:30AM  The Zacks Analyst Blog Highlights: General Electric, GlaxoSmithKline and McDonald
09:29AM  Battle of the Pharmaceutical Bigwigs: GlaxoSmithKline vs. Pfizer
08:03AM  3 Stocks to Avoid in Healthcare at Motley Fool
Sep-27-16 11:45AM  New Research Reports for GE, McDonald's & GSK
Sep-26-16 05:50PM  Frances Essilor Said to Hire Glaxos Halper as Head of M&A at Bloomberg
09:33AM  The Internet of Medical Things: 6 Stocks in Focus
08:56AM  Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.
06:25AM  Apple iPhone Calling Big Pharma: We Can Help You Develop Better Drugs at Motley Fool
Sep-25-16 11:10AM  3 Bold Bets on the Future of Biotechnology at Motley Fool
Sep-24-16 10:00AM  5 Stocks to Sell Now Before It's Too Late
Sep-23-16 07:54AM  [$$] GSK's 'fiercely competitive' Emma Walmsley faces test of experience at Financial Times
Sep-22-16 11:12AM  Hard to swallow: emerging markets get tougher for drugmakers
10:48AM  The Pros and Cons of Buying Gilead Sciences Stock at Motley Fool
10:45AM  HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target
Sep-21-16 10:05AM  Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment
01:01AM  Inside the 10-Year, $1 Billion Battle for the Next Critical Antibiotic at Bloomberg
Sep-20-16 07:38PM  PRESS DIGEST- Financial Times - Sept 21 Reuters
03:30PM  Medecins Sans Frontieres Happy with GlaxoSmithKline PLC (ADR) (GSK) Price Reduction For Synflorix at Insider Monkey
11:25AM  GlaxoSmithKline Appoints Big Pharma's First Woman Chief Executive at Forbes
11:05AM  Big Pharmas Latest Breakthrough: Choosing Its First Female CEO
10:46AM  Breaking the mould: GSK picks Big Pharma's first female CEO
09:05AM  GlaxoSmithKline (GSK) Stock Lower, Names Walmsley CEO
07:14AM  Glaxo CEO's Potential Achilles Heel at Bloomberg
07:00AM  GlaxoSmithKline Appoints Insider Walmsley as new CEO
06:22AM  5 Things You Must Know Before the Market Opens Tuesday
06:10AM  GlaxoSmithKline names insider Emma Walmsley as new CEO
05:04AM  UPDATE 2-GlaxoSmithKline names insider Emma Walmsley as new CEO Reuters
04:16AM  GSK names Emma Walmsley as new chief executive
02:13AM  GlaxoSmithKline names consumer head Walmsley new CEO
02:04AM  Glaxo Names Emma Walmsley as New CEO to Succeed Andrew Witty at Bloomberg
Sep-19-16 05:04PM  British pharma group GSK picks new CEO AFP
11:01AM  The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution at Motley Fool
08:04AM  Roche Goes Up against Bristol-Myers Squibb in Oncology Drug Space
07:34AM  GSK cuts vaccine price for refugees, bowing to pressure
Sep-18-16 06:46PM  GSK CEO: Pharma firms need to be empathetic
Sep-16-16 12:42PM  Drugmakers Must Report Clinical Trial Results Once Kept Secret
11:15AM  Drugmakers Must Report Clinical Trial Results Once Kept Secret at Bloomberg
09:05AM  Epizyme Receives Milestone from Glaxo for Lymphoma Drug
08:04AM  Roches Oncology Wheelhouse Stacked with Competitive Drugs
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company's wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company's nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc has collaboration agreements with Universite de Sherbrooke and Pfizer Inc.; development agreement, and R and D collaboration with Propeller Health; R and D collaboration agreement with Valneva SE; and collaboration and license agreement with Idera pharmaceuticals, Inc. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom.